CN114573476A - Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases - Google Patents
Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases Download PDFInfo
- Publication number
- CN114573476A CN114573476A CN202210225334.3A CN202210225334A CN114573476A CN 114573476 A CN114573476 A CN 114573476A CN 202210225334 A CN202210225334 A CN 202210225334A CN 114573476 A CN114573476 A CN 114573476A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- diamine
- benzyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 88
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 150000004985 diamines Chemical class 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
- 230000023852 carbohydrate metabolic process Effects 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 67
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 12
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 230000036542 oxidative stress Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 46
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 25
- -1 acyl diamine Chemical class 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 238000010898 silica gel chromatography Methods 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 238000002390 rotary evaporation Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- IDGQXGPQOGUGIX-SECBINFHSA-N (2r)-2-amino-3-phenylmethoxypropanoic acid Chemical compound OC(=O)[C@H](N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-SECBINFHSA-N 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 150000001263 acyl chlorides Chemical class 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 210000001640 nerve ending Anatomy 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 108010053754 Aldehyde reductase Proteins 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 abstract description 17
- 229950010170 epalrestat Drugs 0.000 abstract description 16
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000013641 positive control Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 208000018914 glucose metabolism disease Diseases 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 102000016912 Aldehyde Reductase Human genes 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 64
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- 239000007787 solid Substances 0.000 description 33
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- TVFIOVJIUUWDCR-LLVKDONJSA-N (2r)-2-acetamido-3-phenylmethoxypropanoic acid Chemical compound CC(=O)N[C@@H](C(O)=O)COCC1=CC=CC=C1 TVFIOVJIUUWDCR-LLVKDONJSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- LZEHLBJBGBCCSS-FMIVXFBMSA-N NC(C=C1)=CC=C1NC(/C(\C#N)=C/C(C=C1)=CC=C1O)=O Chemical compound NC(C=C1)=CC=C1NC(/C(\C#N)=C/C(C=C1)=CC=C1O)=O LZEHLBJBGBCCSS-FMIVXFBMSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- XZJQDVKQYIHTMA-MUIAGPEESA-N CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC(O)=C1O)=O)=O)=O Chemical compound CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC(O)=C1O)=O)=O)=O XZJQDVKQYIHTMA-MUIAGPEESA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000003837 chick embryo Anatomy 0.000 description 4
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 4
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CJMWBHLWSMKFSM-XVNBXDOJSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoic acid Chemical class OC(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 CJMWBHLWSMKFSM-XVNBXDOJSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- WUXZHWGQHZSYNH-RUZDIDTESA-N CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(C(C=CC1=C2)=CC1=CC=C2O)=O)=O)=O Chemical compound CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(C(C=CC1=C2)=CC1=CC=C2O)=O)=O)=O WUXZHWGQHZSYNH-RUZDIDTESA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003288 aldose reductase inhibitor Substances 0.000 description 3
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 3
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 3
- 229950009041 edaravone Drugs 0.000 description 3
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- KGCDLBUEOHPPJI-UHFFFAOYSA-N (6-hydroxynaphthalen-2-yl)-piperazin-1-ylmethanone Chemical compound C1=CC2=CC(O)=CC=C2C=C1C(=O)N1CCNCC1 KGCDLBUEOHPPJI-UHFFFAOYSA-N 0.000 description 2
- LKBFFDOJUKLQNY-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1F LKBFFDOJUKLQNY-UHFFFAOYSA-N 0.000 description 2
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- KAUQJMHLAFIZDU-UHFFFAOYSA-N 6-Hydroxy-2-naphthoic acid Chemical compound C1=C(O)C=CC2=CC(C(=O)O)=CC=C21 KAUQJMHLAFIZDU-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- QHBLJBLOSBMNAK-XNTDXEJSSA-N C(=O)(OC(C)(C)C)N1CCN(CC1)C(\C(=C\C1=CC(=C(C=C1)O)CO)\C#N)=O Chemical compound C(=O)(OC(C)(C)C)N1CCN(CC1)C(\C(=C\C1=CC(=C(C=C1)O)CO)\C#N)=O QHBLJBLOSBMNAK-XNTDXEJSSA-N 0.000 description 2
- DNUIGFKMNPGVAP-GXDHUFHOSA-N C(=O)(OC(C)(C)C)NC1=CC=C(C=C1)NC(\C(=C\C1=CC(=C(C=C1)O)O)\C#N)=O Chemical compound C(=O)(OC(C)(C)C)NC1=CC=C(C=C1)NC(\C(=C\C1=CC(=C(C=C1)O)O)\C#N)=O DNUIGFKMNPGVAP-GXDHUFHOSA-N 0.000 description 2
- PWMKOSRGQZGWPS-NTCAYCPXSA-N C(=O)(OC(C)(C)C)NC1=CC=C(C=C1)NC(\C(=C\C1=CC=C(C=C1)O)\C#N)=O Chemical compound C(=O)(OC(C)(C)C)NC1=CC=C(C=C1)NC(\C(=C\C1=CC=C(C=C1)O)\C#N)=O PWMKOSRGQZGWPS-NTCAYCPXSA-N 0.000 description 2
- FPMUOFLJESBJPV-NTCAYCPXSA-N C(=O)(OC(C)(C)C)NC1CCC(CC1)NC(\C(=C\C1=CC=C(C=C1)O)\C#N)=O Chemical compound C(=O)(OC(C)(C)C)NC1CCC(CC1)NC(\C(=C\C1=CC=C(C=C1)O)\C#N)=O FPMUOFLJESBJPV-NTCAYCPXSA-N 0.000 description 2
- WIUXUNKLVCJCGO-GXDHUFHOSA-N CC(C)(C)OC(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC(O)=C1O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC(O)=C1O)=O)=O WIUXUNKLVCJCGO-GXDHUFHOSA-N 0.000 description 2
- KENDJJRHDQWUFP-NTCAYCPXSA-N CC(C)(C)OC(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC=C1O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC=C1O)=O)=O KENDJJRHDQWUFP-NTCAYCPXSA-N 0.000 description 2
- SKIZDVXQYNZXOZ-LYRGBEMXSA-N CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC(CO)=C1O)=O)=O)=O Chemical compound CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC(CO)=C1O)=O)=O)=O SKIZDVXQYNZXOZ-LYRGBEMXSA-N 0.000 description 2
- IFCPJMXMDJSKJR-WLGHQHAYSA-N CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC=C1O)=O)=O)=O Chemical compound CC(ON(CC1=CC=CC=C1)[C@H](CO)C(N(CC1)CCN1C(/C(\C#N)=C/C(C=C1)=CC=C1O)=O)=O)=O IFCPJMXMDJSKJR-WLGHQHAYSA-N 0.000 description 2
- WFODLUUJDYTVCC-JYPDZDFGSA-N CC(ON(CC1=CC=CC=C1)[C@H](CO)C(NC(CC1)CCC1NC(C(C=CC1=C2)=CC1=CC=C2O)=O)=O)=O Chemical compound CC(ON(CC1=CC=CC=C1)[C@H](CO)C(NC(CC1)CCC1NC(C(C=CC1=C2)=CC1=CC=C2O)=O)=O)=O WFODLUUJDYTVCC-JYPDZDFGSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- FNICBAGIKWIZCI-KPKJPENVSA-N N#C/C(\C(N1CCNCC1)=O)=C\C(C=C1)=CC(CO)=C1O Chemical compound N#C/C(\C(N1CCNCC1)=O)=C\C(C=C1)=CC(CO)=C1O FNICBAGIKWIZCI-KPKJPENVSA-N 0.000 description 2
- RFEVLMOPZCWPHA-YRNVUSSQSA-N N#C/C(\C(N1CCNCC1)=O)=C\C(C=C1)=CC(O)=C1O Chemical compound N#C/C(\C(N1CCNCC1)=O)=C\C(C=C1)=CC(O)=C1O RFEVLMOPZCWPHA-YRNVUSSQSA-N 0.000 description 2
- DJAMJLALNOUUJV-FMIVXFBMSA-N N#C/C(\C(N1CCNCC1)=O)=C\C(C=C1)=CC=C1O Chemical compound N#C/C(\C(N1CCNCC1)=O)=C\C(C=C1)=CC=C1O DJAMJLALNOUUJV-FMIVXFBMSA-N 0.000 description 2
- NZVAPUNDXCISJV-YRNVUSSQSA-N NC1=CC=C(C=C1)NC(\C(=C\C1=CC(=C(C=C1)O)O)\C#N)=O Chemical compound NC1=CC=C(C=C1)NC(\C(=C\C1=CC(=C(C=C1)O)O)\C#N)=O NZVAPUNDXCISJV-YRNVUSSQSA-N 0.000 description 2
- IFYOLBRWYGXSJD-FMIVXFBMSA-N NC1CCC(CC1)NC(\C(=C\C1=CC=C(C=C1)O)\C#N)=O Chemical compound NC1CCC(CC1)NC(\C(=C\C1=CC=C(C=C1)O)\C#N)=O IFYOLBRWYGXSJD-FMIVXFBMSA-N 0.000 description 2
- BXHHHMGYCCPHEG-UHFFFAOYSA-N NCCCNC(=O)C=1C=NC2=CC(=CC=C2C1)O Chemical compound NCCCNC(=O)C=1C=NC2=CC(=CC=C2C1)O BXHHHMGYCCPHEG-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229950010884 ponalrestat Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003069 tolrestat Drugs 0.000 description 2
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- LMVIXHGLBRBILZ-UHFFFAOYSA-N 3,6-dihydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid Chemical compound O1C(C)(C(O)=O)C(O)CC2=C1C(C)=C(C)C(O)=C2C LMVIXHGLBRBILZ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SCXZNYRQOPBUTM-UHFFFAOYSA-N 4-hydroxy-3-(hydroxymethyl)benzaldehyde Chemical compound OCC1=CC(C=O)=CC=C1O SCXZNYRQOPBUTM-UHFFFAOYSA-N 0.000 description 1
- RFVSBXGQVAGYJQ-UHFFFAOYSA-N 7-hydroxyquinoline-3-carboxylic acid Chemical compound C1=C(O)C=CC2=CC(C(=O)O)=CN=C21 RFVSBXGQVAGYJQ-UHFFFAOYSA-N 0.000 description 1
- 101150112656 AKR1B1 gene Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- PCFKMSZNGCUPFD-FPYGCLRLSA-N C(#N)/C(/C(=O)O)=C\C1=CC(=C(C=C1)O)CO Chemical compound C(#N)/C(/C(=O)O)=C\C1=CC(=C(C=C1)O)CO PCFKMSZNGCUPFD-FPYGCLRLSA-N 0.000 description 1
- PCFKMSZNGCUPFD-UHFFFAOYSA-N C(#N)C(C(=O)O)=CC1=CC(=C(C=C1)O)CO Chemical compound C(#N)C(C(=O)O)=CC1=CC(=C(C=C1)O)CO PCFKMSZNGCUPFD-UHFFFAOYSA-N 0.000 description 1
- ITPDQKDPVUKERQ-UHFFFAOYSA-N C(=O)(OC(C)(C)C)N1CCN(CC1)C(=O)C1=CC2=CC=C(C=C2C=C1)O Chemical compound C(=O)(OC(C)(C)C)N1CCN(CC1)C(=O)C1=CC2=CC=C(C=C2C=C1)O ITPDQKDPVUKERQ-UHFFFAOYSA-N 0.000 description 1
- MSZHZCNOATZOMU-XNTDXEJSSA-N C(=O)(OC(C)(C)C)NC1=CC=C(C=C1)NC(\C(=C\C1=CC(=C(C=C1)O)CO)\C#N)=O Chemical compound C(=O)(OC(C)(C)C)NC1=CC=C(C=C1)NC(\C(=C\C1=CC(=C(C=C1)O)CO)\C#N)=O MSZHZCNOATZOMU-XNTDXEJSSA-N 0.000 description 1
- JHBOTYAIEJCXOM-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCC1NC(C(C=CC1=C2)=CC1=CC=C2O)=O)=O Chemical compound CC(C)(C)OC(NC(CC1)CCC1NC(C(C=CC1=C2)=CC1=CC=C2O)=O)=O JHBOTYAIEJCXOM-UHFFFAOYSA-N 0.000 description 1
- WUHCUHNJOCXEBO-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCC1NC(C=CC1=C2)=CC1=CC=C2O)=O Chemical compound CC(C)(C)OC(NC(CC1)CCC1NC(C=CC1=C2)=CC1=CC=C2O)=O WUHCUHNJOCXEBO-UHFFFAOYSA-N 0.000 description 1
- GJSQSVFLKUHXSZ-PUUKEUDRSA-N CC(ON(CC1=CC=CC=C1)[C@H](CO)C(NC(CC1)CCC1NC(C=CC1=C2)=CC1=CC=C2O)=O)=O Chemical compound CC(ON(CC1=CC=CC=C1)[C@H](CO)C(NC(CC1)CCC1NC(C=CC1=C2)=CC1=CC=C2O)=O)=O GJSQSVFLKUHXSZ-PUUKEUDRSA-N 0.000 description 1
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
- XKTNOINOAMZIIO-KPKJPENVSA-N NC(C=C1)=CC=C1NC(/C(\C#N)=C/C(C=C1)=CC(CO)=C1O)=O Chemical compound NC(C=C1)=CC=C1NC(/C(\C#N)=C/C(C=C1)=CC(CO)=C1O)=O XKTNOINOAMZIIO-KPKJPENVSA-N 0.000 description 1
- LPQPCIRXWFUUMU-UHFFFAOYSA-N NC(CC1)CCC1NC(C=CC1=C2)=CC1=CC=C2O Chemical compound NC(CC1)CCC1NC(C=CC1=C2)=CC1=CC=C2O LPQPCIRXWFUUMU-UHFFFAOYSA-N 0.000 description 1
- XAOAFQFECFAUJM-UHFFFAOYSA-N NC1CCC(CC1)NC(=O)C1=CC2=CC=C(C=C2C=C1)O Chemical compound NC1CCC(CC1)NC(=O)C1=CC2=CC=C(C=C2C=C1)O XAOAFQFECFAUJM-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101100108497 Sus scrofa AKR1A1 gene Proteins 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 101150063729 alr1 gene Proteins 0.000 description 1
- 101150003265 alr2 gene Proteins 0.000 description 1
- GCUCIFQCGJIRNT-UHFFFAOYSA-N alrestatin Chemical compound C1=CC(C(N(CC(=O)O)C2=O)=O)=C3C2=CC=CC3=C1 GCUCIFQCGJIRNT-UHFFFAOYSA-N 0.000 description 1
- 229950010242 alrestatin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 description 1
- 229950004311 sorbinil Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The invention discloses a linear head-tail diamine bridged compound, a preparation method thereof and application thereof in preparing a medicament for treating glycometabolism disorder diseases. The compound of the invention has obvious inhibitory activity to aldose reductase and certain oxidation resistance. The application of the compound in preparing the medicine for treating the glucose metabolism disorder diseases, the medicine for treating diabetic complications and the diseases caused by oxidative stress is reported for the first time. Compared with other prior art, the compound has novel structure, simple preparation process and better curative effect than a positive control drug epalrestat.
Description
The application is a divisional application of Chinese patent application with the application number of '202010959328.1', the application date of the original application is '9-14.2020', and the invention name is 'a compound and a preparation method thereof and application thereof in preparing a medicament for treating glycometabolism disorder diseases'.
Technical Field
The invention belongs to the field of medicinal chemistry, and particularly relates to a linear head-tail diamine bridged compound, a preparation method thereof and application thereof in preparing a medicament for treating glycometabolism disorder diseases.
Background
Diabetes Mellitus (DM) is an endocrine metabolic syndrome characterized primarily by hyperglycemia and Diabetes, due to insufficient insulin secretion or insulin resistance in the body. Diabetic patients are prone to induce diabetic complications when being in a hyperglycemic state for a long time, and the diabetic complications are mainly classified into three types: retinopathy, such as: glaucoma, cataract, and the like; peripheral neuropathies, such as: peripheral neuritis, foot ulcer, etc.; kidney disorders, such as: renal microangiopathy, which in severe cases can lead to renal failure, uremia, etc.
In addition, the heart and cerebral vessels are possibly diseased, and stroke, cardiac hypertrophy, congestive heart failure and the like can be caused. These complications are all caused by long-term hyperglycemia of the body, which damages the vascular wall and peripheral nerves and greatly increases the risk of cardiovascular diseases.
Although diabetes has always plagued patients' health, it is really life threatening to be a series of complications due to the persistent hyperglycemia in the body. These complications occur in association with excessive activation of Aldose Reductase (AR) in high sugar environments.
Inhibition of AR has been shown to be an effective approach for the treatment of diabetic complications. According to literature research, although many AR inhibitors have been developed, few aldose reductase inhibitors are available for clinical use, which are effective and have fewer adverse reactions. Among the aldose reductase inhibitors that are commercially available and chemically synthesized are epalrestat (epalrestat), astatin (alrestatin), ponalrestat (ponalrestat), sorbinil (sorbinel) and tolrestat (tolrestat). These drugs are also not ideal. The development of aldose reductase inhibitors with definite therapeutic effect and safety is urgent.
The Chinese patent of invention ZL201410723116.8 and ZL201710372369.9 both disclose a compound having aldose reductase inhibitory activity, but the compound of patent ZL201410723116.8 has less AR inhibitory activity than that of the positive control drug Epasitah and has less antioxidant activity than Trolox; although the patent ZL201710372369.9 found candidate compounds with good AR inhibitory activity and antioxidant activity, its stability and bioavailability were deficient and further improvement was needed.
Disclosure of Invention
In view of the above, the primary object of the present invention is to provide a novel linear head-to-tail diamine bridged compound having both aldose reductase inhibitory activity and antioxidant activity.
Another object of the present invention is to provide a process for producing the above compound.
The invention also aims to provide the application of the compound in preparing medicaments for treating glucose metabolism disorder diseases, in particular to the application in preparing medicaments for treating diabetic complications.
The purpose of the invention is realized by the following technical scheme:
a linear head-to-tail diamine bridged compound having a structure represented by formula I:
in the structure of formula I, the X group has a structure as shown in formula II-1, formula II-2 or formula II-3:
in the structures shown in the formula II-1, the formula II-2 and the formula II-3, R is monohydroxy substituent, dihydroxy substituent or hydroxy and hydroxymethyl substituent;
preferably, when R is monohydroxy, the substitution position in the formula II-1 can be 5-, 6-, 7-, 8-, preferably 6-; the substitution positions in the formulae II-2 and II-3 can be 5-, 6-, 7-, 8-, preferably 7-.
Preferably, R is a dihydroxy substitution, or when hydroxy and hydroxymethyl are disubstituted, an ortho substitution is provided;
further preferably, when R is a dihydroxy group, the substitution position in the formula II-1, the formula II-2 and the formula II-3 may be 5,6-, 6, 7-or 7, 8-;
further preferably, when R is a hydroxyl group and a hydroxymethyl group, the substitution position in the formula II-1 is preferably 6-hydroxyl-7-hydroxymethyl; the substitution position thereof in the formulae II-2 and II-3 is preferably 6-hydroxymethyl-7-hydroxy.
In the structure shown in the formula I, p is 1-6;
the Z group is methyl, isopropyl or cyclopropyl.
Preferably, the compounds of the present invention are specific compounds as shown in table 1:
TABLE 1
The invention also claims pharmaceutically acceptable salts of the compounds having the structure shown in the formula I and the specific compounds shown in the table 1.
The invention also claims synthetic intermediates (or prodrugs) of compounds of the structure shown in formula I and specific compounds shown in Table 1.
A method for preparing a compound having a structure represented by formula I, comprising the steps of:
(1) preparation of N-t-Butoxyacyl protected substituted acyl diamine: dissolving carboxylic acid in a solvent, adding a coupling reagent with the molar weight of 1.0-3.0 times of that of the carboxylic acid, stirring and reacting for 10-40 min at the temperature of-20-0 ℃, then adding head and tail diamine with one end protected by N-tert-butoxy acyl and the organic base with the molar weight of 1.0-3.0 times of that of the carboxylic acid, stirring and reacting for 30-60 min at the temperature of-20-0 ℃, heating to 30-60 ℃, and continuing stirring and reacting for 24-36 h; after the reaction is finished, removing the solvent by rotary evaporation, and purifying the concentrate by silica gel column chromatography to obtain acyl head-tail diamine protected by one end of N-tert-butoxy acyl;
the carboxylic acid has a structure shown in a formula II-1 ', a formula II-2 ' or a formula II-3 ':
the head and tail diamine protected by one end of N-tert-butoxy acyl has a structure shown in a formula III-1':
(2) mono-acyl head-to-tail diamine at one end: dissolving acyl head and tail diamine protected by one end of N-tert-butoxy acyl in a solvent, slowly adding a 4M hydrochloric acid solution of which the molar weight is 5-20 times that of the acyl head and tail diamine protected by one end of N-tert-butoxy acyl, and stirring and reacting for 3-6 hours at 0-40 ℃; after the reaction is finished, removing the solvent by rotary evaporation, and freeze-drying to obtain end-to-end monoacyl diamine;
(3) preparation of N-acylated-O-benzyl-D-serine: adding an acylation reagent with the molar weight of 1.0-5.0 times that of O-benzyl-D-serine into O-benzyl-D-serine, stirring and reacting for 4-9 h at 50-100 ℃, removing the solvent by rotary evaporation, and separating and purifying the concentrate by using high performance liquid chromatography to obtain N-acylation-O-benzyl-D-serine;
(4) preparation of a compound of the structure of formula I: dissolving N-acylation-O-benzyl-D-serine in a solvent, adding a coupling reagent with the molar weight of 1.0-3.0 times that of the N-acylation-O-benzyl-D-serine, and stirring and reacting at-20-0 ℃ for 10-40 min to obtain a solution A; dissolving the monoacyl end-to-end diamine prepared in the step (2) in a solvent, adding organic alkali with the molar weight 3.0-5.0 times that of the monoacyl end-to-end diamine, cooling to below-30 ℃, dropwise adding the solution A under stirring, keeping the temperature after dropwise adding, and stirring for 1-3 hours; heating to room temperature, and continuing to react for 20-40 h; after the reaction is finished, removing the solvent by rotary evaporation; purifying the concentrate by silica gel column chromatography to obtain a compound with a structure shown in formula I;
the solvent used in the steps (1) and (4) is N, N-Dimethylformamide (DMF) or Dichloromethane (DCM)/DMF mixed solution with the volume ratio of 10: 1.
The coupling reagent used in the steps (1) and (4) can be one of ethyl chloroformate, 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC. HCl), N-diisopropyl carbodiimide (DIC) and benzotriazole-1-yl-oxy-tripyrrolidinyl phosphorus hexafluorophosphate (PyBOP) and N-hydroxybenzotriazole (HOBt) mixed according to a molar ratio of 1: 1.
The organic base used in steps (1) and (4) is triethylamine or Diisopropylethylamine (DIPEA).
The solvent used in the step (2) is one of methanol, ethanol and DMF.
The acylating agent used in the step (3) is acid anhydride or acyl chloride.
In the step (4), the molar ratio of the N-acylated-O-benzyl-D-serine to the one-end monoacyl head-tail diamine is 1 (1-3), and preferably 1.0: 1.1.
In still another aspect, the invention also provides the application of the compounds (the compounds with the structure shown in the formula I and the compounds listed in the table 1) in the preparation of medicines for treating glucose metabolism disorder diseases, in particular to the application in the preparation of medicines for treating diabetic complications. These diabetic complications include diabetic retinopathy, diabetic peripheral neuropathy, and diabetic senile dementia.
The present invention has demonstrated that the above-mentioned compounds (structural compounds of formula I and compounds listed in Table 1) have excellent inhibitory activity against aldose reductase using the following experiments: the inhibition rate of alpha-cyano-3, 4-dihydroxycinnamic acid derivatives (namely the compounds of the invention) on the enzymatic hydrolysis activity of aldose reductase is determined by taking D, L-glyceraldehyde as a substrate, and Epalrestat (Epalrestat), a clinical drug, is taken as a positive control. The results showed that (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (. alpha. -cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine (CHR-5N-G) had the best inhibitory activity against human aldose reductase, IC50The value was 12.26. + -. 0.85nmol/L, which is greater than the epalrestat level (IC)5075.64 +/-4.22 nmol/L) and is stronger than CHR-532R (IC) reported by patent CN 201410723116.85089.71 +/-3.51 nmol/L) which is stronger than CHR-5N-D (IC) reported in patent CN201710372369.95041.02 ± 2.83 nmol/L). Other compounds of the invention also exhibit certain inhibitory activity against aldose reductase in vitro.
The compound (the compound with the structure shown in the formula I and the compound listed in the table 1) is inspected to eliminate the free radical generated by 1, 1-diphenyl-2-trinitrophenyl hydrazine (DPPH), and CHR-5N-F is found to show excellent antioxidation, and the half clearing concentration EC is50The concentration is 8.81 +/-0.51 mu M and is obviously stronger than that of a positive control drug Trolox (EC)5014.39 ± 0.23 μ M). Other compounds of the invention also exhibit some free radical scavenging ability.
The effect of CHR-5N-G as a test agent and Epalrestat as a positive control agent and Edaravone as an antioxidant on chick embryo survival, mortality, neural tube teratogenesis, and chick embryo morphology and body weight under a high sugar environment (0.4 mmol/eg) was examined by reference to experimental methods reported in the literature (Zhang L, Li YF, Yuan S, et al, scientific Reports,2016,6: 24942). The results show that the survival rate, the death rate, the total aberration rate and the body weight of the chick embryos treated by the CHR-5N-G are 78.8 percent, 20.7 percent, 11.3 percent and 243.2mg respectively at the concentration of 500 nM; the survival rate, the death rate, the total distortion rate and the body weight of the chick embryos treated by the epalrestat are 69.6 percent, 29.8 percent, 27.9.0 percent and 231.4mg respectively; the survival rate, the death rate, the total distortion rate and the body weight of the chicken embryos treated by the edaravone are 71.2 percent, 30.4 percent, 22.3 percent and 228.5mg respectively. The result shows that the effect of the tested medicament CHR-5N-G is generally superior to that of epalrestat and edaravone.
Meanwhile, the compound has specific inhibitory activity on AR, shows obvious enzyme inhibitory activity on ALR2, is superior to a positive control drug, and has consistent in-vitro activity result with the result of the in-vitro activity; the ALR1 does not show obvious inhibitory activity to the isozyme, so that the target compound has high selectivity on inhibiting AR. The compound remarkably inhibits the polyalcohol pathway of glucose metabolism by inhibiting the activity of AR, and prevents the generation of a metabolite sorbitol of the pathway. The in vivo antioxidant experiment also shows that the compound can obviously inhibit the formation of oxidation product MDA in embryoid bodies, and the ORAC level shows that the compound has good free radical scavenging capacity. The experiments strongly prove that the compound CHR-5N-G can play a good role in protecting the chicken embryonic neural tube deformity induced by high sugar, and secondly, the in-vivo enzyme inhibition activity and the in-vivo antioxidant activity of the compound are outstanding, which are consistent with the in-vitro experiments, and meanwhile, the expression of the regulatory protein Pax 3 can be obviously improved.
A diabetic peripheral neuropathy rat model is established according to a reference document (Neural Regeneration Research 2016,11(2),345 and 351), and CHR-5N-G has an obvious therapeutic effect on high-sugar induced peripheral neuropathy.
Therefore, the compounds (the structural compound of the formula I and the compounds listed in the table 1, and the pharmaceutically acceptable salts and synthetic intermediates thereof) can be used for preparing medicaments for treating glucose metabolism disorder diseases, and particularly can be used for preparing medicaments for treating diabetic complications such as diabetic retinopathy, diabetic senile dementia, nerve ending disorder and the like; the compounds can be used for preparing medicaments for treating diseases caused by oxidative stress, especially diabetic complications.
Compared with the prior art, the invention has the following advantages and effects:
the inhibitory activity of the compound on aldose reductase and the application of the compound in preparing medicaments for treating glycometabolism disorder diseases, medicaments for treating diabetic complications and diseases caused by oxidative stress are reported for the first time. Compared with other prior art, the compound has novel structure, simple preparation process and better curative effect than a positive control drug epalrestat.
Drawings
FIG. 1 is a diagram of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (alpha-cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine (CHR-5N-G)1H NMR spectrum.
FIG. 2 is a diagram of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (alpha-cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine (CHR-5N-G)13C MRC map.
FIG. 3 is an HR-ESI-MS spectrum of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (. alpha. -cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine (CHR-5N-G).
FIG. 4 is a bar graph of the in vitro ALR2 enzyme inhibition rates of a portion of the compounds.
FIG. 5 is a bar graph of free radical scavenging rates for different concentrations of Trolox, CHR-5N-G, CHR-5N-F.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the present invention is not limited thereto.
Example 1
(E) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (4-hydroxyphenyl) acrylamide (CHR-5F-B) comprising the following five steps:
(1) synthesis of (E) - α -cyano-4-hydroxycinnamic acid: 122.1mg (1.0mmol) of 4-hydroxybenzaldehyde is weighed into a dry 50mL round bottom flask, 85mg (1.0mmol) of cyanoacetic acid and 15.4mg (0.2mmol) of ammonium acetate are added, 48mg (0.8mmol) of glacial acetic acid is weighed into the reaction system by a syringe, 10mL of toluene is added as a solvent, and a small-sized water separator, a condenser tube and a drying tube are connected onto a reaction bottle. The reaction was stirred and refluxed for 18h in an oil bath at 120 ℃. Cooling to room temperature after the reaction is finished, standing at low temperature, filtering, and adding dichloromethane into filter cakeWashed three times with DCM to give a yellow solid in 92.8% yield.1H NMR(300MHz,CD3OD)δ:9.66(s,1H,Ar-OH),8.21(s,1H,＝CH-),7.46(d,2H,J＝8.3Hz,Ar-H),6.88(d,J＝8.3Hz,2H,Ar-H)；ESI-MS(m/z):188.3[M-H]-。
(2) Preparation of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-4-hydroxycinnamamide: 1.89g (10.0mmol) of alpha-cyano-4-hydroxycinnamic acid was added to a 100mL round bottom flask, 30mL of DCM/DMF (10:1 (V/V)) was added and dissolved with stirring, 1.15g (11.0mmol) of weighed EDC & HCl was added to the flask, and the reaction was stirred at 0 ℃ for 10min, then 0.82g (11.0mmol) of weighed HOBt was added to the reaction flask and the reaction was stirred at 0 ℃ for 10min to activate the free carboxyl group sufficiently. After the carboxyl group was sufficiently activated, 2.29g (11.0mmol) of 4-N-Boc-aminoaniline and 4.6mL (26.4mmol) of DIPEA were measured by syringe, and injected into the reaction flask in sequence, stirred at 0 ℃ for reaction for about 30min, slowly warmed to room temperature, and reacted for 24 h. After the reaction, the solvent was removed, and the residue was separated and purified by silica gel column chromatography (chloroform: methanol: 40:1) to obtain 3.29g of a yellow solid, which was obtained in 86.7% yield.1H NMR(400MHz,DMSO-d6)δ:10.03(s,Ar-NH),9.34(s,Ar-NH),8.75(s,Ar-OH),8.45(s,＝CH),7.75(m,4H,Ar),7.45(d,J＝8.3Hz,2H,Ar-H),6.46(d,J＝8.3Hz,2H,Ar-H),1.48(CH3,9H)；13C NMR(101MHz,DMSO-d6)δ:163.8,157.7,152.5,150.4,143.2,133.6,133.2,124.7,121.8,115.8,106.9,79.5,28.4。
(3) Preparation of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamamide: (E) -N- (N-Boc-4-aminophenyl) - α -cyano-4-hydroxycinnamamide 1.14g (3.0mmol) was dissolved in 30mL of dry methanol, transferred to a 50mL round-bottomed flask, and 7.5mL of a 4mol/L HCl solution (30mmol) was slowly added dropwise thereto, and the reaction was stirred at room temperature for 4 hours. The solvent was removed to give a pale yellow solid in 97.3% yield.1H NMR(400MHz,DMSO-d6)δ:10.03(s,1H,Ar-NH),8.75(s,1H,Ar-OH),8.45(s,1H,＝CH),7.45(d,J＝8.3Hz,2H,Ar-H),7.38(d,J＝8.1Hz,2H,Ar-H),6.58(d,J＝8.3Hz,2H,Ar-H),6.32(d,J＝8.1Hz,2H,Ar-H),4.53(br,2H,Ar-NH2)；13C NMR(101MHz,DMSO-d6)δ:163.8,157.7,152.5,150.4,143.2,133.6,133.2,124.7,121.8,115.8,106.9。
(4) N-acetyl-O-benzyl-preparation of D-serine: 195.2mg (1.0mmol) of O-benzyl-D-serine is weighed into a 50mL round-bottom flask, dissolved in 10mL redistilled methanol, 0.3mL (about 3mmol) of acetic anhydride and 0.5mL (about 3mmol) of DIEA are weighed into a syringe and added into the reaction system, and the reflux reaction is carried out for 7h at 70 ℃. After the reaction, methanol in the reaction solution was removed under reduced pressure, and unreacted acetic anhydride was removed by freeze-drying. HPLC preparation (mobile phase methanol: water 50:50, 0.05% TFA, uv 254nm) gave a colorless oil, 74.5% yield.1H NMR(400MHz,CDCl3)δ:11.63(s,1H,-COOH),7.26(m,5H,Ar-H),7.04(d,J＝7.8Hz,1H,-CO-NH-),4.79-4.67(m,1H,-N-CH-),4.47(s,2H,Ar-CH2-O-),3.82-3.78(m,2H,-CH2-O-),2.01(s,3H,-CO-CH3)；13C NMR(75MHz,CDCl3)δ172.98,171.69,137.45,128.61,128.09,127.90,73.53,69.66,52.91,22.92.ESI-MS(m/z):236.7[M-H]-。
(5) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (4-hydroxyphenyl) acrylamide: weighing 118.7mg (0.5mmol) of N-acetyl-O-benzyl-D-serine in a penicillin bottle, sequentially adding 101.5mg (0.75mmol) of HOBt and 144mg (0.75mmol) of EDC & HCl, and 3-10 mL of DCM/DMF (10:1, V/V) as solvents, and stirring for reaction for 10min to obtain solution A. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) -alpha-cyano-4-hydroxycinnamamide is further weighed and dissolved in 3-10 mL of DCM/DMF, 0.4mL (2.2mmol) of DIPEA is added, the mixture is cooled to-30 ℃, the solution A is dropwise added under stirring, and after the dropwise addition is finished, the temperature is kept and the stirring is carried out for 1 hour. Then, the reaction was allowed to warm to room temperature and continued for 23 h. After the reaction is finished, the solvent is removed by rotary evaporation. The resulting extract was subjected to silica gel column chromatography (chloroform: methanol: 40:1, V: V) and gradient elution to obtain 181.1mg of a pale yellow solid with a yield of 66.1%.1H NMR(300MHz,DMSO-d6)δ:9.67(s,1H),8.17(d,J＝8.0Hz,3H),7.37–7.23(m,11H,＝CH,Ar-H),6.52(d,J＝8.7Hz,2H),4.65(d,J＝7.9Hz,1H),4.50(d,J＝3.8Hz,2H),3.61(s,1H),3.12(s,1H),1.88(s,3H,CH3)；13C NMR(101MHz,DMSO-d6)δ:171.80,169.49,167.79,144.76,138.32,138.21,128.37,128.36,127.67,127.65,127.62,127.59,121.25,114.12,72.19,70.13,69.75,53.79,53.34,52.44,42.02,22.68,22.51,18.27,16.92,12.63.ESI-MS(m/z):499.2for C28H26N4O5([M+H]+)；
(C＝1,CH3OH)。
The above data confirm that the compound is (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) -alpha-cyano-3- (4-hydroxyphenyl) acrylamide (CHR-5F-B), and the structure is shown below.
Example 2
(E) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminocyclohexyl) - α -cyano-3- (4-hydroxyphenyl) acrylamide (CHR-5F-E) comprising the following five steps.
(1) Preparation of (E) -alpha-cyano-4-hydroxycinnamic acid. Same procedure as in (1) of example 1
(2) Preparation of (E) -N- (N-Boc-4-aminocyclohexyl) - α -cyano-4-hydroxycinnamamide: the procedure was as in (2) of example 1. 2.29g (11.0mmol) of 4-N-Boc-aminocyclohexylamine was changed to 2.36g (11.0mmol) of 4-N-Boc-aminocyclohexylamine, giving 2.29g of a pale yellow solid in 59.5% yield.1H NMR(300MHz,DMSO-d6)δ:10.50(s,1H,Ar-OH),8.31(s,1H),8.15(s,1H),7.85(s,1H),7.77(d,J＝8.2Hz,2H),6.94(d,J＝8.2Hz,2H),3.70(m,1H),3.43(m,1H),1.66(m,4H),1.51(m,4H),1.38(s,9H)；13C NMR(75MHz,DMSO-d6)δ:161.64,160.97,154.91,150.00,132.72,122.95,117.31,116.18,101.68,77.46,46.97,28.29,28.08,26.84。
(3) Preparation of (E) -N- (4-aminocyclohexyl) - α -cyano-4-hydroxycinnamamide: the procedure was as in (3) of example 1. The (E) -N- (N-Boc-4-aminocyclohexyl) - α -cyano-4-hydroxycinnamamide obtained in the above step was added to give 1.67g of a light brown solid, yield 89.6%.1H NMR(300MHz,DMSO-d6)δ:10.50(s,1H,Ar-OH),8.33(s,1H),8.17(s,1H),7.52(d,J＝8.1Hz,2H),6.63(d,J＝8.1Hz,2H),3.65(m,1H),2.58(m,1H),1.73(m,4H),1.52(br,2H),1.47(m,4H)；13C NMR(75MHz,DMSO-d6)δ:161.65,160.96,150.01,132.73,122.97,117.33,116.17,101.69,46.98,28.32,28.10。
(4) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(5) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminocyclohexyl) - α -cyano-3- (4-hydroxyphenyl) acrylamide: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamamide was replaced by 156.9mg (0.55mmol) of (E) -N- (4-aminocyclohexyl) - α -cyano-4-hydroxycinnamamide. The resulting mixture was subjected to silica gel column chromatography (chloroform: methanol: 40:1, V: V) and gradient elution to obtain 174.3mg of a pale yellow solid with a yield of 62.8%.1H NMR(300MHz,CDCl3)δ:9.72(s,1H,Ar-OH),8.32(br,2H),8.16(s,1H),8.13(br,1H),7.89(d,J＝8.7Hz,2H,Ar-H),7.40-7.28(m,5H,Ar-H),6.98(d,J＝8.7Hz,2H,Ar-H),4.75(m,1H),4.63(s,2H),4.03-3.84(m,3H),3.64-3.46(m,2H),2.05(s,3H,CH3),1.74(m,4H),1.51(m,4H)；13C NMR(75MHz,CDCl3)δ:161.4,160.7,154.9,150.7,149.4,143.2,137.5,132.8,128.6,122.4,117.7,116.8,101.8,77.3,69.7,57.3,50.6,46.9,28.7,26.9.ESI-MS(m/z):503.6for C28H32N4O5([M-H]+)；
(C＝2,CH3OH)。
The above data confirmed that this compound is (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminocyclohexyl) - α -cyano-3- (4-hydroxyphenyl) acrylamide (CHR-5F-E), and the structure is shown below.
Example 3
(E) Preparation of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (. alpha. -cyano-3- (4-hydroxyphenyl) acryloyl) piperazine (CHR-5F-G) comprising the following five steps:
(1) preparation of (E) -alpha-cyano-4-hydroxycinnamic acid. Same procedure as in (1) of example 1
(2) Preparation of (E) -4-Boc-1- (α -cyano-4-hydroxycinnamoyl) piperazine: the procedure was as in (2) of example 1. 2.29g (11.0mmol) of 4-N-Boc-aminoaniline was changed to 2.05g (11.0mmol) of N-Boc-piperazine. 1.89g of light yellow solid is obtained, and the yield is 52.9%.1H NMR(400MHz,CDCl3)δ:9.68(s,1H),8.12(s,1H),7.83(d,J＝8.7Hz,2H),6.97(d,J＝8.7Hz,2H),3.55-3.51(m,8H),1.48(s,9H)；13C NMR(101MHz,CDCl3)δ:163.97,160.14,154.43,152.81,132.69,124.48,116.60,116.15,101.31,80.56,50.91,48.82,28.21。
(3) Preparation of (E) - α -cyano-4-hydroxycinnamoylpiperazine: the procedure was as in (3) of example 1. The (E) -4-Boc-1- (alpha-cyano-4-hydroxycinnamoyl) piperazine obtained in the above step was charged to give 1.23g of a light brown solid, and the yield was 90.5%.1H NMR(400MHz,CDCl3)δ:9.69(s,1H),8.13(s,1H),7.82(d,J＝8.7Hz,2H),6.96(d,J＝8.7Hz,2H),3.36(m,4H),2.87(m,4H),1.23(br,1H)；13C NMR(101MHz,CDCl3)δ:164.12,154.45,152.83,133.21,124.53,116.62,116.17,101.35,80.56,51.62,47.13。
(4) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(5) Preparation of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (α -cyano-3- (4-hydroxyphenyl) acryloyl) piperazine: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamoyl amide was replaced with 141.5mg (0.55mmol) of (E) - α -cyano-4-hydroxycinnamoyl piperazine. Purifying by silica gel column chromatography (chloroform: methanol: 40:1, V: V) with gradient elution to obtain light yellow solid 132.6mg with yield of 50.6%.1H NMR(400MHz,DMSO-d6)δ:9.72(s,1H,Ar-OH),8.56(s,1H),8.15(s,1H),7.52(d,J＝8.7Hz,2H),7.42(m,5H,Ar-H),6.69(d,J＝8.7Hz,2H),4.76(m,1H),4.63(s,2H),3.62(m,1H),3.53(m,4H),3.41(m,4H),3.32(m,2H),2.04(s,3H,CH3)；13C NMR(101MHz,DMSO-d6)δ:171.73,169.75,168.12,157.87,151.43,144.25,138.52,129.61,128.82,127.40,124.70,115.80,115.60,106.90,72.30,70.0,54.80,49.40,48.90,22.90；ESI-MS(m/z):499.5for C26H28N4O5([M+Na]+)；
(C＝2,CH3OH).
The above data demonstrate that the compound is (E) -4- (N-acetyl-O-benzyl-D-serinyl) -1- (α -cyano-3- (4-hydroxyphenyl) acryloyl) piperazine (CHR-5F-G), having the structure:
example 4
(E) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (3, 4-dihydroxyphenyl) acrylamide (CHR-5N-B) comprising the following five steps:
(1) synthesis of (E) - α -cyano-3, 4-dihydroxycinnamic acid: 138mg (1.0mmol) of 3, 4-dihydroxybenzaldehyde is weighed into a dry 50mL round bottom flask, 85mg (1.0mmol) of cyanoacetic acid and 15.4mg (0.2mmol) of ammonium acetate are added, 48mg (0.8mmol) of glacial acetic acid is weighed into the reaction system by a syringe, 10mL of toluene is added as a solvent, and a small-sized water separator, a condenser tube and a drying tube are connected onto a reaction bottle. The reaction was stirred and refluxed for 18h in an oil bath at 120 ℃. After the reaction was completed, the reaction mixture was cooled to room temperature, then allowed to stand at a low temperature, filtered, and the filter cake was washed three times with Dichloromethane (DCM) to obtain 196.3mg of a yellow solid with a yield of 95.7%.1H NMR(300MHz,CD3OD)δ:9.52(s,2H,Ar-OH),8.21(s,1H,＝CH-),7.64(d,J＝8.3Hz,1H),7.36(s,1H,Ar-H),6.88(d,J＝8.3Hz,1H,Ar-H)；ESI-MS(m/z):204.3for C10H6NO4([M-H]-)。
(2) Preparation of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-3, 4-dihydroxycinnamamide: the same procedure as in (2) of example 1 was repeated except for replacing 1.89g (10.0mmol) of α -cyano-4-hydroxycinnamic acid with 2.05g (10.0mmol) of α -cyano-3, 4-dihydroxycinnamic acid. 2.82g of a yellow solid was obtained with a yield of 71.3%.1H NMR(400MHz,DMSO-d6)δ:10.03(s,1H),9.34(s,1H,Ar-NH),8.75(s,2H,2×Ar-OH),8.45(s,1H,＝CH),7.75(m,4H,Ar),7.66(d,J＝8.3Hz,1H),7.38(s,1H,Ar-H),6.89(d,J＝8.3Hz,1H,Ar-H),1.49(s,9H,3×CH3)；13C NMR(101MHz,DMSO-d6)δ:163.8,157.7,152.5,150.4,143.2,133.6,133.2,124.7,121.8,115.8,106.9,79.5,28.4。
(3) Preparation of (E) -N- (4-aminophenyl) - α -cyano-3, 4-dihydroxycinnamamide: the procedure was the same as in example 1, step (3), except that 1.14g (3.0mmol) of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-4-hydroxycinnamide was replaced with 1.19g (3.0mmol) of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-3, 4-dihydroxycinnamamide. Pale yellow solid was obtained in 96.4% yield.1H NMR(400MHz,DMSO-d6)δ:10.05(s,1H,Ar-NH-),8.77(s,2H,2×Ar-OH),8.46(s,1H,＝CH),7.76(d,J＝7.6Hz,2H,Ar-H),7.65(d,J＝8.3Hz,1H),7.36(s,1H,Ar-H),6.87(d,J＝8.3Hz,1H,Ar-H),6.53(d,J＝7.6Hz,2H,Ar-H),4.56(br,2H)；13C NMR(101MHz,DMSO-d6)δ:163.9,151.8,150.2,142.6,133.4,132.8,124.6,121.7,115.6,106.8。
(4) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(5) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (3, 4-dihydroxyphenyl) acrylamide: 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamide was replaced with 162.4mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-3, 4-dihydroxycinnamamide, the procedure was as in example 1, step (5). The resulting product was purified by silica gel column chromatography (chloroform: methanol: 40:1, V: V) and gradient elution to obtain 152.2mg of a pale yellow solid (yield: 53.8%).1H NMR(300MHz,DMSO-d6)δ:10.18(s,1H,-CONH-Ar),9.62(s,1H,Ar-NHCO-),9.47(s,2H,2×Ar-OH),8.34(d,J＝18.2Hz,1H),7.96(s,1H,＝CH),7.65(d,J＝6.2Hz,2H),7.59(d,J＝6.2Hz,2H),7.51(d,J＝8.5Hz,1H),7.25(m,5H,Ar-H),7.11(s,1H),6.85(d,J＝8.5Hz,1H),5.05(d,J＝13.1Hz,1H,CO-CH-N),4.65(s,2H,Ar-CH2-O),3.55(s,1H,O-CH2),3.07(s,1H,O-CH2),1.80(s,3H,CH3)；13C NMR(75MHz,DMSO-d6)δ:172.81,171.23,163.92,150.56,146.92,144.76,137.53,134.31,133.42,129.33,128.62(2),127.87,127.65,127.62,123.20,121.25(4),117.29,115.76,115.32,109.51,72.29,69.75,56.63,22.92.ESI-MS(m/z):545.7for C28H26N4O6([M+Na]+).
(C＝2，CH3OH)。
The above data demonstrate that the compound is (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) -alpha-cyano-3- (3, 4-dihydroxyphenyl) acrylamide (CHR-5N-B) and has the following structure:
example 5
(E) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (3-hydroxymethyl-4-hydroxyphenyl) acrylamide (CHR-5N-C) comprising the following five steps:
(1) synthesis of (E) - α -cyano-3-hydroxymethyl-4-hydroxycinnamic acid: the procedure was carried out in the same manner as in example 4, step (1) except for replacing 138mg (1.0mmol) of 3, 4-dihydroxybenzaldehyde with 152.1mg (1.0mmol) of 3-hydroxymethyl-4-hydroxybenzaldehyde. 204.9mg of a yellow solid are obtained with a yield of 93.5%.1H NMR(300MHz,CD3OD)δ:9.62(s,H,Ar-OH),8.26(s,1H,＝CH-),7.54(d,J＝8.3Hz,1H),7.32(d,J＝8.3Hz,1H,Ar-H),7.14(s,1H,Ar-H),7.02(br,1H),4.63(s,2H)；ESI-MS(m/z):218.4for C11H8NO4([M-H]-)。
(2) Preparation of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-3-hydroxymethyl-4-hydroxycinnamamide: the same procedure as in example 1, step (2), was repeated except for replacing 1.89g (10.0mmol) of α -cyano-4-hydroxycinnamic acid with 2.19g (10.0mmol) of α -cyano-3-hydroxymethyl-4-hydroxycinnamic acid. 3.01g of a yellow solid was obtained in a yield of 73.2%.1H NMR(400MHz,DMSO-d6)δ:10.13(s,1H,-CO-NH-Ar),9.84(s,1H,Ar-NH-Boc-),9.72(s,1H,Ar-OH),8.45(s,1H,＝CH),7.75(m,4H,Ar),7.66(d,J＝8.3Hz,1H),7.38(d,J＝8.3Hz,1H,Ar-H),7.14(s,1H,Ar-H),7.06(br,1H),4.63(s,2H,Ar-CH2-O),1.51(s,9H,3×CH3)；13C NMR(101MHz,DMSO-d6)δ:163.8,156.13,153.06,150.51,133.62,133.25,129.60,128.83,128.18,126.20,121.76(4),115.84,107.11,79.53,61.12,29.05(3)。
(3) Preparation of (E) -N- (4-aminophenyl) - α -cyano-3-hydroxymethyl-4-hydroxycinnamamide: the same procedure as in example 1, step (2), was repeated except for replacing 1.14g (3.0mmol) of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-3-hydroxymethyl-4-hydroxycinnamide with 1.23g (3.0mmol) of (E) -N- (N-Boc-4-aminophenyl) - α -cyano-4-hydroxycinnamide. This gave 88.7mg of a pale yellow solid, yield 95.6%.1H NMR(400MHz,DMSO-d6)δ:10.15(s,1H,Ar-NH-),9.77(s,1H,Ar-OH),8.21(s,1H,＝CH),7.52(d,J＝7.6Hz,1H,Ar-H),7.43(d,J＝8.3Hz,2H),7.37(d,J＝7.6Hz,1H,Ar-H),7.21(s,1H,Ar-H),6.33(d,J＝8.3Hz,2H,Ar-H),4.56(br,2H)；13C NMR(101MHz,DMSO-d6)δ:163.9,156.14,150.52,133.63,133.26,129.63,128.85,128.17,126.22,121.78(4),115.85,107.12,61.13。
(4) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(5) Preparation of (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (3-hydroxymethyl-4-hydroxyphenyl) acrylamide: 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamide was replaced with 170.1mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-3-hydroxymethyl-4-hydroxycinnamide, and the procedure was the same as in step (5) of example 1. After silica gel column chromatography (chloroform: methanol: 40:1, V: V), the mixture was separated and purified by gradient elution to obtain 157.8mg of a pale yellow solid, which was obtained in 54.3% yield.1H NMR(300MHz,DMSO-d6)δ:10.13(s,1H,-CONH-Ar),9.71(s,1H,Ar-NHCO-),9.57(s,1H,Ar-OH),8.33(d,J＝18.2Hz,1H),8.16(s,1H,＝CH),7.66(d,J＝6.2Hz,2H),7.57(d,J＝6.2Hz,2H),7.53(d,J＝8.5Hz,1H),7.25(m,5H,Ar-H),7.14(s,1H),7.05(br,1H,Bn-OH),6.86(d,J＝8.5Hz,1H),5.07(d,J＝13.1Hz,1H,CO-CH-N),4.68(s,2H,Ar-CH2-O-),4.63(s,2H,Ar-CH2-O),3.56(s,1H,O-CH2),3.08(s,1H,O-CH2),1.82(s,3H,CH3)；13C NMR(75MHz,DMSO-d6)δ:172.83,171.23,164.01,154.87,138.02,134.21,133.34,129.56,128.74,128.63(2),128.06,127.82,127.45(2),126.14,121.85(4),115.12,107.11,72.32,69.11,61.25,57.14,53.34,22.93.ESI-MS(m/z):551.8for C29H28N4O6Na([M+Na]+).
(C＝2，CH3OH)。
The above data demonstrate that this compound is (E) -N- (4- (N-acetyl-O-benzyl-D-seryl) aminophenyl) - α -cyano-3- (3-hydroxymethyl-4-hydroxyphenyl) acrylamide (CHR-5N-C), and has the following structure:
example 6
(E) Preparation of-4- (N-acetyl-O-benzyl-D-seryl) -1- (α -cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine (CHR-5N-G) comprising the following five steps:
(1) the procedure was as in (1) of example 4.
(2) Preparation of (E) -4-Boc-1- (α -cyano-3, 4-dihydroxycinnamoyl) piperazine: the procedure was as in (2) of example 4. 2.29g (11.0mmol) of 4-N-Boc-aminoaniline was changed to 2.05g (11.0mmol) of N-Boc-piperazine. 2.34g of pale yellow solid is obtained with a yield of 62.7%.1H NMR(400MHz,CDCl3)δ:9.57(s,2H,2×OH),8.15(s,1H,＝CH),7.52(d,J＝8.3Hz,1H,Ar-H),7.03(s,1H,Ar-H),6.86(d,J＝8.3Hz,1H,Ar-H),3.55-3.52(m,4H,CH2),3.39(m,4H,CH2),1.40(s,9H,3×CH3)；13C NMR(101MHz,DMSO-d6)δ:163.59,153.98,150.95,146.56,145.84,128.85,124.72,123.81,117.22,116.00,106.17,79.47,51.21(2),49.03(2),28.22(3)。
(3) Preparation of (E) - α -cyano-3, 4-dihydroxycinnamoyl piperazine: the procedure was as in (3) of example 1. The (E) -4-Boc-1- (alpha-cyano-3, 4-dihydroxycinnamoyl) piperazine obtained in the above step was charged to give 1.60g of a light brown solid, and the yield was 93.4%.1H NMR(400MHz,CDCl3)δ:9.63(s,2H,2×OH),8.16(s,1H),7.61(d,J＝8.7Hz,1H),7.03(s,1H,Ar-H),6.93(d,J＝8.7Hz,1H),3.36(m,4H),2.87(m,4H),1.23(br,1H)；13C NMR(101MHz,CDCl3)δ:166.52,150.93,146.55,145.83,128.84,124.73,123.82,117.23,116.00,106.17,51.21(2),47.03(2)。
(4) Preparation of N-acetyl-O-benzyl-D-serine: the procedure is as in (4) of example 1.
(5) Preparation of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (α -cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamide was replaced by 150.3mg (0.55mmol) of (E) - α -cyano-3, 4-dihydroxycinnamoylpiperazine. The resulting product was subjected to silica gel column chromatography (chloroform: methanol: 40:1, V: V) and gradient elution to obtain 145.7mg of a pale yellow solid, which was obtained in 53.8% yield.1H NMR(400MHz,DMSO-d6)δ:9.52(s,2H,2×Ar-OH),8.36(s,1H,Ac-NH-),8.13(s,1H,Ar-CH＝),7.53(d,J＝8.1Hz,1H),7.33(m,5H,Ar-H),7.08(s,1H,Ar-H),6.95(d,J＝8.1Hz,1H),4.75(m,1H,-CO-CH-N-),4.67(s,2H,Ar-CH2 O-),3.62(m,1H),3.53(m,4H),3.39(m,4H),3.33(m,1H),1.86(s,3H,CH3-CO-) (see fig. 1);13C NMR(101MHz,DMSO-d6)δ:172.61,170.13,168.04,151.22,146.63,145.92,138.05,129.31,128.64(2),127.81,127.47(2),123.18,116.97,115.92,115.17,107.15,72.33,69.98,54.91,49.53(2),48.95(2),22.94.ESI-MS(m/z):493.4C26H29N4O6([M+H]+) (see FIG. 2); HR-ESI-MS (m/z):493.2087 (see FIG. 3);
(C＝2,CH3OH).
the above data demonstrate that the compound is (E) -4- (N-acetyl-O-benzyl-D-serinyl) -1- (α -cyano-3- (3, 4-dihydroxyphenyl) acryloyl) piperazine (CHR-5N-G) and has the following structure:
example 7
(E) Preparation of-4- (N-acetyl-O-benzyl-D-seryl) -1- (α -cyano-3- (3-hydroxymethyl-4-hydroxyphenyl) acryloyl) piperazine (CHR-5N-H) comprising the following five steps:
(1) the procedure was as in (1) of example 5.
(2) Preparation of (E) -4-Boc-1- (α -cyano-3-hydroxymethyl-4-hydroxycinnamoyl) piperazine: the procedure was as in (2) of example 5. 2.29g (11.0mmol) of 4-N-Boc-aminoaniline was changed to 2.05g (11.0mmol) of N-Boc-piperazine. 2.55g of light yellow solid is obtained with a yield of 65.8%.1H NMR(400MHz,CDCl3)δ:9.63(s,1H,Ar-OH),8.13(s,1H,＝CH),7.48(d,J＝8.2Hz,1H,Ar-H),7.31(d,J＝8.2Hz,1H,Ar-H),7.13(s,1H,Ar-H),7.05(s,1H,Ar-H),4.65(s,2H,O-CH2-Ar),3.36(m,4H,CH2),3.32(m,4H,CH2),1.43(s,9H,3×CH3)；13C NMR(101MHz,DMSO-d6)δ:167.52,155.46,154.81,150.65,129.85,128.73,128.15,126.32,117.22,116.07,115.85,106.94,79.86,51.03(2),48.81(2),28.52(3)。
(3) Preparation of (E) - α -cyano-3-hydroxymethyl-4-hydroxycinnamoylpiperazine: the procedure was as in (3) of example 1. The (E) -4-Boc-1- (alpha-cyano-3-hydroxymethyl-4-hydroxycinnamoyl) piperazine obtained in the above step was charged to give 1.75g of a light brown solid in a yield of 92.5%.1H NMR(400MHz,CDCl3)δ:9.65(s,1H,Ar-OH),8.16(s,1H,＝CH),7.45(d,J＝8.2Hz,1H,Ar-H),7.29(d,J＝8.2Hz,1H,Ar-H),7.12(s,1H,Ar-H),7.04(s,1H,Ar-H),4.62(s,2H,O-CH2-Ar),3.25(m,4H,CH2),2.82(m,4H,CH2),1.08(br,1H)；13C NMR(101MHz,DMSO-d6)δ:167.71,155.47,150.58,129.93,128.81,128.09,126.26,116.05,115.83,106.96,51.62(2),47.33(2)。
(4) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(5) Preparation of (E) -4- (N-acetyl-O-benzyl-D-seryl) -1- (α -cyano-3- (3-hydroxymethyl-4-hydroxyphenyl) acryloyl) piperazine: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamoyl amide was replaced with 158.1mg (0.55mmol) of (E) - α -cyano-3-hydroxymethyl-4-hydroxycinnamoyl piperazine. After silica gel column chromatography (chloroform: methanol: 40:1, V: V), the mixture was separated and purified by gradient elution to obtain 153.8mg of a pale yellow solid with a yield of 55.2%.1H NMR(400MHz,DMSO-d6)δ:9.63(s,1H,Ar-OH),8.33(s,1H,Ac-NH-),8.12(s,1H,Ar-CH＝),7.49(d,J＝8.2Hz,1H),7.33(m,5H,Ar-H),7.29(d,J＝8.2Hz,1H),7.05(s,1H,Bn-OH),4.76(m,1H,-CO-CH-N-),4.66(s,2H,Ph-CH2O-),4.63(s,2H,Ar-CH2O-),3.59(m,1H),3.48(m,4H),3.36(m,4H),3.32(m,1H),1.87(s,3H,CH3-CO-)；13C NMR(101MHz,DMSO-d6)δ:170.73,169.84,167.23,155.45,150.56,137.52,129.61,128.75,128.62(2),128.03,127.83,127.52(2),126.18,116.06,115.83,107.13,72.35,70.02,60.51,54.93,49.46(2),48.94(2),22.95.ESI-MS(m/z):507.6C27H31N4O6([M+H]+)；
(C＝2,CH3OH).
The above data demonstrate that this compound is (E) -4- (N-acetyl-O-benzyl-D-serinyl) -1- (α -cyano-3- (3-hydroxymethyl-4-hydroxyphenyl) acryloyl) piperazine (CHR-5N-H), having the structure:
example 8
The preparation of N- (4- (N-acetyl-O-benzyl-D-seryl) aminocyclohexyl) -6-hydroxy-beta-naphthamide (CHR-5Y-E1) comprising the following four steps:
(1) preparation of N- (N-Boc-4-aminocyclohexyl) -6-hydroxy- β -naphthylamide: the procedure was as in (2) of example 2. 1.89g (10.0mmol) of 4-hydroxy-alpha-cyanocinnamic acid was changed to 1.88g (10.0mmol) of 6-hydroxy-beta-naphthoic acid to give 3.63g of a pale yellow solid with a yield of 94.5%.1H NMR(300MHz,DMSO-d6)δ:9.99(s,1H,OH),8.33(s,1H,＝CH-CO),8.07(m,1H,Ar-H),7.85(m,2H,Ar-H),7.72(m,2H),7.46(m,1H),7.26(m,1H),3.88(m,1H),3.46(m,1H),1.78(s,4H,CH2),1.59(s,4H,CH2),1.39(s,9H,3×CH3)；13C NMR(101MHz,DMSO-d6)δ:166.95,157.73,154.99,134.94,131.48(2),130.92,129.09,127.41,126.65,125.75,124.70,119.32,108.62,77.44,53.76,51.61,28.71(2),28.63(2),28.41(3)。
(2) Preparation of N- (4-aminocyclohexyl) -6-hydroxy- β -naphthylamide: the procedure was as in (3) of example 1. The N- (N-Boc-4-aminocyclohexyl) -6-hydroxy-beta-naphthamide obtained in the above step was added to give a light brown solid (2.45 g), yield 91.2%.1H NMR(300MHz,DMSO-d6)δ:9.28(s,1H,OH),8.31(s,1H),8.08(m,1H,Ar-H),7.83(m,2H,Ar-H),7.72(m,1H),7.46(s,1H),7.28(m,1H),3.88(m,1H),3.55(m,1H),2.58(m,1H),1.78(m,2H,CH2),1.73(m,2H),1.54(m,2H),1.51(m,2H)；13C NMR(101MHz,DMSO-d6)δ:167.23,158.13,133.54,131.81,131.32,130.93,128.29,126.67,124.73,118.35,109.14,51.65,50.32,31.41(2),28.73(2)。
(3) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(4) Preparation of N- (4- (N-acetyl-O-benzyl-D-seryl) aminocyclohexyl) -6-hydroxy- β -naphthylamide: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamamide was replaced by 156.4mg (0.55mmol) of N- (4-aminocyclohexyl) -6-hydroxy- β -naphthamide. The resulting extract was subjected to silica gel column chromatography (chloroform: methanol: 40:1, V: V) and gradient elution to obtain 181.4mg of a pale yellow solid with a yield of 65.5%.1H NMR(300MHz,CDCl3)δ:10.06(s,1H,OH),8.34(s,1H,Ac-NH-),8.31(s,1H,Ar-H),8.14(d,J＝7.4Hz,1H,-NH-CO-),8.08(d,J＝8.7Hz,1H,Ar-H),7.81(m,2H,Ar-H),7.72(d,J＝8.7Hz,1H,Ar-H),7.45(s,1H,Ar-H),7.34(m,5H,Ar-H),7.26(m,1H,Ar-H),4.67(m,1H,CO-CH-NH),4.62(s,2H,Ar-O-CH2-),3.58(m,1H),3.53(m,2H),3.34(m,1H),1.88(s,3H,CH3-CO-),1.81(m,2H),1.76(m,2H),1.53(m,2H),1.49(m,2H)；13C NMR(101MHz,DMSO-d6)δ:171.42,170.69,167.18,158.14,138.25,135.95,130.49,129.07,128.20,127.45,126.62,125.75,124.76,119.36,108.63,72.03,70.29,52.49,46.84,45.22,28.01,27.47,22.56.ESI-MS(m/z):526.7C29H33N3O5([M+Na]+)；
(C＝2,CH3OH)。
The above data confirm that this compound is N- (4- (N-acetyl-O-benzyl-D-seryl) aminocyclohexyl) -6-hydroxy- β -naphthamide (CHR-5Y-E1), the structure of which is shown below.
Example 9
The preparation of 4- (N-acetyl-O-benzyl-D-seryl) -1- (6-hydroxy- β -naphthoyl) piperazine (CHR-5Y-G) comprises the following four steps:
(1) preparation of 4-Boc-1- (6-hydroxy- β -naphthoyl) piperazine: the procedure was as in (2) of example 3. 1.89g (10.0mmol) of 4-hydroxy-alpha-cyanocinnamic acid was replaced with 1.88g (10.0mmol) of 6-hydroxy-beta-naphthoic acid to give 2.34g of a pale yellow solid in 65.8% yield.1H NMR(400MHz,CD3OD)δ:9.23(s,1H,OH),8.31(s,1H,Ar-H),8.08(d,J＝8.5Hz,1H,Ar-H),7.77(d,J＝9.7Hz,1H,Ar-H),7.69(d,J＝8.5Hz,1H,Ar-H),7.41(s,1H,Ar-H),7.26(d,J＝9.7Hz,1H，Ar-H),3.61(m,4H,CH2),3.35(m,4H),1.47(s,9H,3×CH3)；13C NMR(101MHz,CD3OD)δ:172.87,157.82,155.95,136.89,131.81,131.32,130.89,128.47,126.59,125.12,120.26,118.33,109.70,81.39,50.92(2),49.81(2),28.39。
(2) Preparation of 6-hydroxy- β -naphthoylpiperazine: the procedure was as in (3) of example 1. The 4-Boc-1- (6-hydroxy-. beta. -naphthoyl) piperazine obtained in the above step was charged to give 1.55g of a pale brown solid, yield 91.8%.1H NMR(400MHz,CD3OD)δ:9.21(s,1H,OH),8.29(s,1H,Ar-H),8.10(d,J＝8.3Hz,1H,Ar-H),7.79(d,J＝9.5Hz,1H,Ar-H),7.68(d,J＝8.3Hz,1H,Ar-H),7.43(s,1H,Ar-H),7.28(d,J＝9.5Hz,1H，Ar-H),3.48(m,4H,CH2),2.92(m,4H)；13C NMR(101MHz,CD3OD)δ:169.02,158.23,134.04,131.78,131.29,130.89,128.36,126.65,124.80,118.33,109.20,52.67(2),47.11(2)。
(3) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(5) Preparation of 4- (N-acetyl-O-benzyl-D-seryl) -1- (6-hydroxy- β -naphthoyl) piperazine: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamamide was replaced with 141.0mg (0.55mmol) of 6-hydroxy- β -naphthoylpiperazine. The resulting product was subjected to silica gel column chromatography (chloroform: methanol: 40:1, V: V) and gradient elution to separate and purify the product, to obtain 136.8mg of a pale yellow solid, with a yield of 52.3%.1H NMR(400MHz,DMSO-d6)δ:9.98(s,1H,Ar-OH),8.35(d,J＝8.1Hz,1H,Ar-H),8.30(s,1H,Ar-H),8.25(d,J＝8.2Hz,1H,Ar-H),7.84(d,J＝8.6Hz,1H,Ar-H),7.68(d,J＝8.2Hz,1H),7.32(m,5H,Ar-H),7.28(d,J＝8.6Hz,1H,Ar-H),4.75(m,1H,-CO-CH-N-),4.62(s,2H,Ar-CH2-O),3.58(m,1H),3.61(m,4H),3.52(m,4H),3.35(m,1H),1.85(s,3H,CH3CO-)；13C NMR(101MHz,DMSO-d6)δ:170.59,169.72,168.85,158.19,137.56,134.07,131.18,130.93,128.65(2),128.27,127.61,127.53,127.46,126.90,126.71,126.13,124.87,119.43,108.66,72.19,69.64,50.02(2),49.42(2),22.93.ESI-MS(m/z):474.5C27H29N3O5([M-H]+)；
(C＝2,CH3OH).
The above data demonstrate that this compound is 4- (N-acetyl-O-benzyl-D-seryl) -1- (6-hydroxy- β -naphthoyl) piperazine (CHR-5Y-G) and has the following structure:
example 10
The preparation of 3-N- (N-acetyl-O-benzyl-D-seryl) -7-hydroxy-3-quinolinecarboxylatepropanediamine (CHR-5H) comprises the following four steps:
(1) preparation of N- (3-N-Boc-aminopropyl) -7-hydroxy-3-quinolinecarboxamide: the procedure was as in (2) of example 1. 1.89g (10.0mmol) of 4-hydroxy- α -cyanocinnamic acid was replaced by 1.89g (10.0mmol) of 7-hydroxy-3-quinolinecarboxylic acid; 2.29g (11.0mmol) of 4-N-Boc-aminoaniline was replaced with N-Boc-1,3-propanediamine 1.92g (11.0mmol) gave 2.51g of a pale yellow solid in a yield of 72.7%.1H NMR(400MHz,DMSO-d6)δ:9.42(s,1H,Ar-OH),8.83(s,1H,-C-CH＝C-),8.63(s,1H,-N＝CH-),8.35(m,1H，ArCO-NH-),7.90(d,J＝8.9Hz,1H,NH),7.47(m,2H,Ar-H),6.80(m,1H,-NH-Boc),3.21(m,4H),1.78(m,2H),1.37(s,9H,3×CH3)；13C NMR(101MHz,DMSO-d6)δ:166.1,160.5,156.1,149.7,146.5,136.3,131.6,125.9,124.6,119.1,110.5,79.7,39.6,37.3,28.8,28.5(3)。
(2) Preparation of N- (3-aminopropyl) -7-hydroxy-3-quinolinecarboxamide: the procedure was as in (3) of example 1. The N- (3-N-Boc-aminopropyl) -7-hydroxy-3-quinolinecarboxamide obtained in the above step was charged to give 1.54g of a light brown solid in a yield of 95.3%.1H NMR(400MHz,DMSO-d6)δ:9.39(s,1H,Ar-OH),8.81(s,1H,-C-CH＝C-),8.64(s,1H,-N＝CH-),8.34(m,1H,ArCO-NH-),7.87(d,J＝8.9Hz,1H,NH),7.45(m,2H,Ar-H),3.19(m,2H),2.69(m,2H),1.89(m,2H)；13C NMR(101MHz,DMSO-d6)δ:165.8,160.3,149.6,146.4,136.1,131.7,125.8,124.5,119.2,110.6,39.2,35.8,28.6。
(3) Preparation of N-acetyl-O-benzyl-D-serine: the procedure was as in (4) of example 1.
(4) Preparation of 3-N- (N-acetyl-O-benzyl-D-seryl) -7-hydroxy-3-quinolinecarboxylatepropanediamine: the procedure was as in (5) of example 1. 153.6mg (0.55mmol) of (E) -N- (4-aminophenyl) - α -cyano-4-hydroxycinnamamide was replaced by 134.9mg (0.55mmol) of N- (3-aminopropyl) -7-hydroxy-3-quinolinecarboxamide. After silica gel column chromatography (chloroform: methanol: 40:1, V: V), the mixture was separated and purified by gradient elution to obtain 167.8mg of a pale yellow solid with a yield of 65.7%.1H NMR(400MHz,DMSO-d6)δ:10.49(s,1H,OH),9.13(s,1H,＝CH-CO),8.65(s,1H,-N＝CH-),8.43(s,1H,ArCO-NH-),8.33(m,1H,Ac-NH-),8.03(m,1H,-NH-CO),7.90(d,J＝8.8Hz,1H,Ar-H),7.47(m,2H,Ar-H),7.32(m,5H),4.74(m,1H,CO-CH-N),4.61(s,2H,-CH2-OAr),3.61(m,1H),3.32(m,1H),3.17(m,4H),2.36(m,2H),1.85(s,3H,CH3CO-)；13C NMR(101MHz,DMSO-d6)δ:173.32,170.91,165.73,160.22,150.65,149.16,137.90,136.15,131.64,128.56(2),127.69,127.42(2),125.48,124.38,120.88,119.06,110.11,73.00,70.11,57.44,39.52,37.35,28.67,22.25.ESI-MS(m/z):465.6C25H28N4O5([M+H]+)；
(C＝2,CH3OH).
The above data demonstrate that this compound is 3-N- (N-acetyl-O-benzyl-D-seryl) -7-hydroxy-3-quinolinecarboxylatepropanamine (CHR-5H), and has the following structure:
according to the synthetic routes and methods of the compounds of formula I disclosed in the present application, and the synthetic methods of the specific compounds of examples 1-10, those skilled in the art can adjust the raw materials involved in the synthetic methods according to the structures of the target products, so as to synthesize other compounds listed in table 1, which are not listed here.
Example 11
Inhibitory Activity of Compounds in Table 1 against aldose reductase
In the present invention, Aldose Reductase (AR), reduced coenzyme II (NADPH), DL-glyceraldehyde were purchased from Sigma; epalrestat (Epalrestat) was purchased from tokyo chemical industry co.
The experimental steps are as follows: the enzyme reaction system is carried out on a 96-well plate, and comprises: PBS buffer (pH 6.2)100 μ L, 1.5mmol/L NADPH 20 μ L, 100mmol/L DL-glyceraldehyde 20 μ L, different concentration (Epalrestat or test sample) solutions 20 μ L, AR dilutions 20 μ L, distilled water 20 μ L. The experimental setup was blank control, standard control, enzyme metabolism group as in table 2-1.
TABLE 2-1 grouping and dosing
Note: all volume units above are μ L.
After the liquid is incubated for 5min at 37 ℃,20 mu L of AR is added into each group except a blank solvent group to start reaction, a 96-well plate is rapidly placed into a fluorescence microplate reader, the temperature is 37 ℃, the detection wavelength is 340nm, the change condition of NADPH absorbance is continuously detected, the detection is carried out once every 30s, and the total detection time is 30 min.
According to the results measured by the experiment, the descending values A of blank group NADPH absorbance are respectively calculated0Decrease in enzyme Activity group (No sample) NADPH Absorbance A1NADPH absorbance decrease values A of the Epalrestat group and the test sample groupEPS、A2. The inhibition rate was determined by using the change in NADPH absorbance of each group:
sample inhibition rate for AR/% - [1- (a)2-A0)/(A1-A0)]×100％。
According to the enzyme reaction experiment result, the final concentration of the sample is used as the abscissa, the inhibition rate is used as the ordinate, an inhibition curve is drawn, and the IC of different samples is calculated according to the kinetic curve50. All data are used
Data statistics are shown to be processed by the SPSS10.0 software, with the inter-group comparisons tested with t. IC of positive control Epalrestat was determined5075.64 + -4.22. Obtaining IC of target end product by the above method50The results are shown in Table 2-2:
TABLE 2-2 IC of the target Compounds50Value of
As can be seen from Table 2-2 and FIG. 4, the compound CHR-5N-G has the best inhibitory activity on aldose reductase in vitro, which is significantly stronger than the positive control drug epalrestat, and is also significantly stronger than the compound CHR-532R reported in patent CN 201410723116.8 and the compound CHR-5N-D reported in patent CN 201710372369.9;
except that the compounds CHR-5N-E, CHR-5Y-1 and CHR-5H-E, CHR-5H-G, CHR-5H-H showed weaker enzyme inhibitory activity than the positive drug epalrestat, the in vitro inhibitory activity of other compounds on aldose reductase is stronger than that of the positive control drug.
Example 12
In vitro antioxidant Activity of the Compounds in Table 1
In this embodiment, Trolox (6-Hydroxy-2,5,7, 8-tetramethylhydroxychroman-2-carboxylic acid); 1, 1-diphenylyl-2-piperidinylhydrazyl (DPPH) was purchased from Sigma.
The experimental steps are as follows: the reaction system was performed in a 96-well plate, and 40. mu.L of each sample solution was added to the 96-well plate, and then 160. mu.L of DPPH solution was added in parallel to each well. A control group (40. mu.L methanol + 160. mu.L DPPH) and a blank group (40. mu.L test sample + 160. mu.L methanol) were also set. Shaking for 1min to mix well, standing 96-well plate in dark condition for 0.5 hr, quickly placing the plate in microplate reader, and detecting wavelength at 517 nm. The final absorbance (A) values were measured and each sample was run in triplicate and averaged. The clearance rate is calculated as follows:
radical scavenging rate (%) ═ aControl of－(ASample(s)－ABlank space))/AControl×100％
AControl ofAbsorbance of control group without sample;
Asample (I)Is the absorbance of the reaction solution after the test sample is added;
Ablank spaceAbsorbance of blank group.
All data are used
Data statistics are shown to be processed by the SPSS10.0 software, with the t-test for inter-group comparisons. The results are shown in Table 3-1.
TABLE 3-1 inhibition of DPPH by the target Compounds at a concentration of 100. mu.M
The inhibition of DPPH by the compounds examined at 100. mu.M is shown in Table 3-1. As can be seen from Table 3-1, all the compounds examined showed a certain degree of free radical scavenging rate, wherein the in vitro antioxidant activity of CHR-5Y-2, CHR-5Y-3 and CHR-5Y-E2 is stronger than that of the positive control Trolox.
For compounds with outstanding inhibitory activity and positive controls, to facilitate comparison of their inhibitory activity, a histogram of concentration-inhibition at three concentrations of 25 μ M, 12.5 μ M, 6.25 μ M is generated as shown in FIG. 5:
the half clearing concentration of Trolox, CHR-5Y-2 and CHR-5Y-3, namely EC is obtained by linear regression analysis of the logarithm of the concentration and the inhibition rate of the compound50The results are shown in Table 3-2.
TABLE 3-2 Compounds correspond to EC50Value of
As can be seen from the results of Table 3-2, the compounds CHR-5Y-2 and CHR-5Y-3 are superior in oxidation resistance and stronger than the positive drug Trolox.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. A linear head-to-tail diamine bridged compound characterized by having the structure shown in formula I:
in the structure of formula I, the X group has a structure as shown in formula II-1, formula II-2 or formula II-3:
in the structures shown in the formula II-1, the formula II-2 and the formula II-3, R is monohydroxy substituent, dihydroxy substituent or hydroxy and hydroxymethyl substituent;
the Z group is methyl, isopropyl or cyclopropyl.
2. The compound of claim 1, wherein: r is a dihydroxy substitution or when hydroxy and hydroxymethyl are disubstituted, ortho substitution is performed.
3. The compound of claim 1, wherein: in the structure shown in the formula I, p is 1-6.
4. The compounds shown in table 1:
TABLE 1
5. A pharmaceutically acceptable salt of a compound of any one of claims 1 to 4.
6. A process for the preparation of a compound according to claims 1-3, characterized in that it comprises the following steps:
(1) preparation of N-t-Butoxyacyl protected substituted acyl diamine: dissolving carboxylic acid in a solvent, adding a coupling reagent with the molar weight of 1.0-3.0 times that of the carboxylic acid, stirring and reacting for 10-40 min at-20-0 ℃, then adding a head-tail diamine with one end protected by N-tert-butoxy acyl and an organic base with the molar weight of 1.0-3.0 times that of the carboxylic acid, stirring and reacting for 30-60 min at-20-0 ℃, heating to 30-60 ℃, and continuing stirring and reacting for 24-36 h; after the reaction is finished, removing the solvent by rotary evaporation, and purifying the concentrate by silica gel column chromatography to obtain acyl head-tail diamine protected by one end of N-tert-butoxy acyl;
the carboxylic acid has a structure shown in a formula II-1 ', a formula II-2 ' or a formula II-3 ':
the head and tail diamine protected by one end of N-tert-butoxy acyl has a structure shown in a formula III-1':
(2) mono-acyl head-to-tail diamine at one end: dissolving acyl head and tail diamine protected by one end of N-tert-butoxy acyl in a solvent, slowly adding a 4M hydrochloric acid solution of which the molar weight is 5-20 times that of the acyl head and tail diamine protected by one end of N-tert-butoxy acyl, and stirring and reacting for 3-6 hours at 0-40 ℃; after the reaction is finished, removing the solvent by rotary evaporation, and freeze-drying to obtain end-to-end monoacyl diamine;
(3) preparation of N-acylated-O-benzyl-D-serine: adding an acylation reagent with the molar weight of 1.0-5.0 times that of O-benzyl-D-serine into O-benzyl-D-serine, stirring and reacting for 4-9 h at 50-100 ℃, removing the solvent by rotary evaporation, and separating and purifying the concentrate by using high performance liquid chromatography to obtain N-acylation-O-benzyl-D-serine;
(4) preparation of a compound of the structure of formula I: dissolving N-acylation-O-benzyl-D-serine in a solvent, adding a coupling reagent with the molar weight of 1.0-3.0 times that of the N-acylation-O-benzyl-D-serine, and stirring and reacting at-20-0 ℃ for 10-40 min to obtain a solution A; dissolving the monoacyl end-to-end diamine prepared in the step (2) in a solvent, adding organic alkali with the molar weight 3.0-5.0 times that of the monoacyl end-to-end diamine, cooling to below-30 ℃, dropwise adding the solution A under stirring, keeping the temperature after dropwise adding, and stirring for 1-3 hours; heating to room temperature, and continuing to react for 20-40 h; after the reaction is finished, removing the solvent by rotary evaporation; purifying the concentrate by silica gel column chromatography to obtain a compound with a structure shown in formula I;
the acylating agent used in the step (3) is acid anhydride or acyl chloride.
7. Use of a compound according to any one of claims 1 to 4 or a salt according to claim 5 for the manufacture of a medicament for the treatment of disorders of carbohydrate metabolism.
8. Use of a compound according to any one of claims 1 to 4 or a salt according to claim 5 for the manufacture of a medicament for the treatment of a disease caused by oxidative stress.
9. Use of a compound according to any one of claims 1 to 4 or a salt according to claim 5 in the manufacture of a medicament for the treatment of diabetic complications.
10. Use according to claim 9, characterized in that: the diabetic complications comprise diabetic retinopathy, diabetic nerve ending disorder and diabetic senile dementia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210225334.3A CN114573476A (en) | 2020-09-14 | 2020-09-14 | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210225334.3A CN114573476A (en) | 2020-09-14 | 2020-09-14 | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases |
| CN202010959328.1A CN112500314B (en) | 2020-09-14 | 2020-09-14 | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010959328.1A Division CN112500314B (en) | 2020-09-14 | 2020-09-14 | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114573476A true CN114573476A (en) | 2022-06-03 |
Family
ID=74953447
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210224154.3A Active CN114656371B (en) | 2020-09-14 | 2020-09-14 | 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism |
| CN202010959328.1A Active CN112500314B (en) | 2020-09-14 | 2020-09-14 | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases |
| CN202210225352.1A Pending CN114656372A (en) | 2020-09-14 | 2020-09-14 | P-phenylenediamine bridged compound and application thereof in preparation of medicines for treating glycometabolism disorder diseases |
| CN202210225334.3A Pending CN114573476A (en) | 2020-09-14 | 2020-09-14 | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210224154.3A Active CN114656371B (en) | 2020-09-14 | 2020-09-14 | 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism |
| CN202010959328.1A Active CN112500314B (en) | 2020-09-14 | 2020-09-14 | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases |
| CN202210225352.1A Pending CN114656372A (en) | 2020-09-14 | 2020-09-14 | P-phenylenediamine bridged compound and application thereof in preparation of medicines for treating glycometabolism disorder diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN114656371B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447406A (en) * | 2014-11-27 | 2015-03-25 | 陈河如 | Alpha-cyano-4-hydroxy cinnamic acid derivative and preparation method and application thereof |
| CN107082754A (en) * | 2017-05-24 | 2017-08-22 | 广州药本君安医药科技股份有限公司 | A kind of cinnamic acid derivative with aldose reductase inhibition activity and its production and use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003245711A1 (en) * | 2002-02-11 | 2003-09-04 | Pfizer Inc. | Nicotinamide derivatives useful as pde4 inhibitors |
| US20110224147A1 (en) * | 2008-08-01 | 2011-09-15 | Relevare Aust. Pyt. Ltd. | Methods and compositions |
| JP6420314B2 (en) * | 2013-04-10 | 2018-11-07 | シンデブルックス，インコーポレイティド | METAP2 inhibitor and method for treating obesity |
-
2020
- 2020-09-14 CN CN202210224154.3A patent/CN114656371B/en active Active
- 2020-09-14 CN CN202010959328.1A patent/CN112500314B/en active Active
- 2020-09-14 CN CN202210225352.1A patent/CN114656372A/en active Pending
- 2020-09-14 CN CN202210225334.3A patent/CN114573476A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447406A (en) * | 2014-11-27 | 2015-03-25 | 陈河如 | Alpha-cyano-4-hydroxy cinnamic acid derivative and preparation method and application thereof |
| CN107082754A (en) * | 2017-05-24 | 2017-08-22 | 广州药本君安医药科技股份有限公司 | A kind of cinnamic acid derivative with aldose reductase inhibition activity and its production and use |
Non-Patent Citations (1)
| Title |
|---|
| ZHANG LAITAO等: "Bioactivity focus of a-cyano-4-hydroxycinnamic acid （CHCA）leads to effecitve multifunctional aldose reductase inhibitors", SCIENTIFIC REPORTS, vol. 6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114656372A (en) | 2022-06-24 |
| CN112500314A (en) | 2021-03-16 |
| CN114656371B (en) | 2024-03-12 |
| CN112500314B (en) | 2022-05-13 |
| CN114656371A (en) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2298295B1 (en) | Tumor necrosis factor inhibitors | |
| CN1040323C (en) | Novel compounds | |
| JPH0415221B2 (en) | ||
| CN109678715B (en) | Salt, the preparation method and the usage that 2- (1- acyl-oxygen n-pentyl) benzoic acid and basic amino acid or aminoguanidine are formed | |
| CN104447406B (en) | Alpha-cyano-4-hydroxy cinnamic acid derivative and preparation method and application thereof | |
| CN1711249A (en) | Quinazolinone derivatives useful as anti-hyperalgesic agents | |
| KR20100087300A (en) | Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof | |
| CN108997282B (en) | Arylbenzofuran derivatives having alpha-glucosidase inhibitory activity | |
| Wang et al. | Synthesis and biological evaluation of novel neoflavonoid derivatives as potential antidiabetic agents | |
| JP4991537B2 (en) | Cis-1,2-substituted stilbene derivatives and their use in the manufacture of a medicament for the treatment and / or prevention of diabetes | |
| CN114573476A (en) | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | |
| CN107445935B (en) | Hesperetin analog derivative and its preparation that a kind of amide groups replaces and as the application in anti-inflammatory drug | |
| CN114920710A (en) | Urea derivatives | |
| CN114349700B (en) | Oxidized isoaporphine alkaloid derivative, preparation method and anti-depression application thereof | |
| CN107082754B (en) | A kind of cinnamic acid derivative and its preparation method and application with aldose reductase inhibition activity | |
| CN114149386A (en) | Aryl pentadiene amide aldehyde dehydrogenase inhibitor, and synthesis method and application thereof | |
| CN1688566A (en) | Remedies | |
| JPH07215959A (en) | Chroman derivative | |
| JPS61286359A (en) | N-((5-(trifluoromethyl)-6-methoxy-1-naphthalenyl) thioxomethyl or carbonyl)-n-methylglycineamide | |
| EP2723719B1 (en) | Piperazine derivatives, their preparation processes and their uses in the treatment of insulinoresistance | |
| CN111393372A (en) | Benzimidazole derivative and preparation method and application thereof | |
| JPH08143556A (en) | Dioxothiazolidine derivative and medicinal composition containing the same derivative | |
| CN111057015B (en) | 2- (4-phenyl-1H-1, 2, 3-triazole-1-yl) acetic acid and acethydrazide compounds | |
| CN113307815B (en) | Trifluoromethyl spliced double-spiro chromanone skeleton pyrrole oxindole compound and preparation method and application thereof | |
| RU2066322C1 (en) | 3-(4-methyl-2-thiazolyl)-6-propyl-7-(1-methyl-1-ethoxycarbonyl)-methoxychromone showing hypoglycemic, hypolipidemic and analeptic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |